DaVita (DVA) to Release Earnings on Tuesday

DaVita (NYSE:DVA) will likely be posting its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect DaVita to post earnings of $2.33 per share and revenue of $3.3564 billion for the quarter. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the firm posted $2.24 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. On average, analysts expect DaVita to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

DaVita Price Performance

NYSE DVA opened at $151.80 on Friday. The business has a 50 day simple moving average of $151.18 and a 200 day simple moving average of $131.48. DaVita has a one year low of $101.00 and a one year high of $159.42. The stock has a market capitalization of $10.14 billion, a P/E ratio of 15.32, a P/E/G ratio of 0.53 and a beta of 0.84.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Truist Financial set a $158.00 target price on DaVita in a research note on Thursday, February 5th. Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. TD Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, UBS Group raised their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $155.80.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Atlas Capital Advisors Inc. bought a new position in shares of DaVita in the fourth quarter valued at approximately $139,000. Zions Bancorporation National Association UT lifted its holdings in shares of DaVita by 533.1% in the fourth quarter. Zions Bancorporation National Association UT now owns 1,032 shares of the company’s stock valued at $117,000 after purchasing an additional 869 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of DaVita in the third quarter valued at approximately $115,000. Aster Capital Management DIFC Ltd bought a new position in shares of DaVita in the fourth quarter valued at approximately $105,000. Finally, Gen Wealth Partners Inc lifted its holdings in DaVita by 10.0% during the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock worth $100,000 after acquiring an additional 80 shares during the period. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.